Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy

Journal of Experimental Medicine

Volumn 203, Issue 3, 2006, Pages 743-753

  Hamaguchi, Yasuhito ^a   Xiu, Yan ^a   Komura, Kazuhiro ^a   Nimmerjahn, Falk ^b   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MB20 1; MONOCLONAL ANTIBODY MB20 11; MONOCLONAL ANTIBODY MB20 14; MONOCLONAL ANTIBODY MB20 16; MONOCLONAL ANTIBODY MB20 18; MONOCLONAL ANTIBODY MB20 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG EVALUATION, PRECLINICAL; IMMUNOGLOBULIN G; LYMPHOCYTE DEPLETION; LYMPHOMA; MICE; MONOCYTES; RECEPTORS, IGG;

EID: 33645053518     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20052283     Document Type: Article

References (48)

1. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2:580-592.
2. Ravetch, J.V. 2003. Fc receptors. In Fundamental Immunology. W.E. Paul, editor. Lippincott-Raven, Philadelphia, PA. 685-700.
3. Davis, R.S., G. Dennis Jr., M.R. Odom, A.W. Gibson, R.P. Kimberly, P.D. Burrows, and M.D. Cooper. 2002. Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol. Rev. 190:123-136.
4. Mechetina, L.V., A.M. Najakshin, B.Y. Alabyev, N.A. Chikaev, and A.V. Taranin. 2002. Identification of CD16-2, a novel mouse receptor homologous to CD16/FcγRIII. Immunogenetics. 54:463-468.
5. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J.V. Ravetch. 2005. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 23:41-51.
6. Clynes, R., J.S. Maizes, R. Guinamard, M. Ono, T. Takai, and J.V. Ravetch. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189:179-185.
7. Kimberly, R.P., J. Wu, A.W. Gibson, K. Su, H. Qun, X. Li, and J.C. Edberg. 2002. Diversity and duplicity: human Fcγ receptors in host defense and autoimmunity. Immunol. Res. 26:177-189.
8. Press, O.W., J.P. Leonard, B. Coiffier, R. Levy, and J. Timmerman. 2001. Immunotherapy of non-Hodgkin's lymphomas. Hematology (Am. Soc. Hematol. Educ. Program). 1:221-240.
9. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:459-465.
10. Weiner, L.M. 1999. Monoclonal antibody therapy of cancer. Semin. Oncol. 26:43-51.
11. Onrust, S.V., H.M. Lamb, and J.A. Balfour. 1999. Rituximab. Drugs. 58:79-88.
12. McLaughlin, P., C.A. White, A.J. Grillo-Lopez, and D.G. Maloney. 1998. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology. 12:1763-1769.
13. Silverman, G.J., and S. Weisman. 2003. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48:1484-1492.
14. Edwards, J.C., and G. Cambridge. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 40:205-211.
15. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J.A. Oliver, K. Bowen, D.A. Steeber, K.M. Haas, J.C. Poe, and T.F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16:119-129.
16. Uchida, J., Y. Hamaguchi, J.A. Oliver, J.V. Ravetch, J.C. Poe, K.M. Haas, and T.F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199:1659-1669.
17. Hamaguchi, Y., J. Uchida, D.W. Cain, G.M. Venturi, J.C. Poe, K.M. Haas, and T.F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174:4389-4399.
18. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-446.
19. Anderson, D.R., A. Grillo-López, C. Varns, K.S. Chambers, and N. Hanna. 1997. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem. Soc. Trans. 25:705-708.
20. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 99:754-758.
21. Anolik, J.H., D. Campbell, R.E. Felgar, F. Young, I. Sanz, J. Rosenblatt, and R.J. Looney. 2003. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455-459.
22. Weng, W.-K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947.
23. Bruhns, P., A. Samuelsson, J.W. Pollard, and J. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-581.
24. Hazenbos, W.L.W., J.E. Gessner, F.M.A. Hofhuis, H. Kuipers, D. Meyer, I.A.F.M. Heijnen, R.E. Schmidt, M. Sandor, P.J.A. Capel, M. Daëron, et al. 1996. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity. 5:181-188.
25. Hazenbos, W.L.W., I.A.F.M. Heijnen, D. Meyer, F.M.A. Hofhuis, C.R. de Lavalette, R.E. Schmidt, P.J.A. Capel, J.G.J. van de Winkel, J.E. Gessner, T.K. van den Berg, and J.S. Verbeek. 1998. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CD16). J. Immunol. 161:3026-3032.
26. Meyer, D., C. Schiller, J. Westermann, S. Izui, W.L.W. Hazenbos, J.S. Verbeek, R.E. Schmidt, and J.E. Gessner. 1998. FcγRIII (CD16)-deficient mice show IgG isotype dependent protection to experimental autoimmune hemolytic anemia. Blood. 92:3997-4002.
27. Gavin, A.L., N. Barnes, H.M. Dijstelbloem, and P.M. Hogarth. 1998. Cutting edge: identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. J. Immunol. 160:20-23.
28. Herlyn, D., and H. Koprowski. 1982. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA. 79:4761-4765.
29. Kaminski, M.S., K. Kitamura, D.G. Maloney, M.J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idio-type therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136:1123-1130.
30. Denkers, E.Y., C.C. Badger, J.A. Ledbetter, and I.D. Bernstein. 1985. Influence of antibody isotype on passive serotherapy of lymphoma. J. Immunol. 135:2183-2186.
31. Liu, A.Y., R.R. Robinson, E.D. Murray Jr., J.A. Ledbetter, I. Hellströom, and K.E. Hellström. 1987. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139:3521-3526.
32. H3 domains on in vivo effector function. J. Immunol. 161:3862-3869.
33. Fossati-Jimack, L., A. Ioan-Facsinay, L. Reininger, Y. Chicheportiche, N. Watanabe, T. Saito, F.M.A. Hofhuis, J.E. Gessner, C. Schiller, R.E. Schmidt, et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191:1293-1302.
34. Ioan-Facsinay, A., S.J. de Kimpe, S.M.M. Hellwig, P.L. van Lent, F.M.A. Hofhuis, H.H. van Ojik, C. Sedlik, S.A. da Silveira, J. Gerber, Y.F. de Jong, et al. 2002. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity. 16:391-402.
35. Camilleri-Broet, S., N. Mounier, A. Delmer, J. Briere, O. Casasnovas, L. Cassard, P. Gaulard, B. Christian, B. Coiffier, and C. Sautes-Fridman. 2004. FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia. 18:2038-2040.
36. Reff, M.E., K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, and N. Hanna. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83:435-445.
37. Maloney, D.G., A.J. Grillo-Lopez, C.A. White, D. Bodkin, R.J. Schilder, J.A. Neidhart, N. Janakiraman, K.A. Foon, T.M. Liles, B.K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:2188-2195.
38. Maloney, D.G., L.A. Grillo, D.J. Bodkin, C.A. White, T.M. Liles, I. Royston, C. Varns, J. Rosenberg, and R. Levy. 1997. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:3266-3274.
39. Winkler, U., M. Jensen, O. Manzke, H. Schulz, V. Diehl, and A. Engert. 1999. Cytokine-release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC- C2B8). Blood. 94:2217-2224.
40. Farag, S.S., I.W. Flinn, R. Modali, T.A. Lehman, D. Young, and J.C. Byrd. 2004. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 103:1472-1474.
41. Coutelier, J.P., J.T. van der Logt, F.W. Heessen, G. Warnier, and J. Van Snick. 1987. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165:64-69.
42. Markine-Goriaynoff, D., and J.P. Coutelier. 2002. Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. J. Virol. 76:432-435.
43. Baldridge, J.R., and M.J. Buchmeier. 1992. Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection. J. Virol. 66:4252-4257.
44. Schlageter, A.M., and T.R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914-1918.
45. Taborda, C.P., J. Rivera, O. Zaragoza, and A. Casadevall. 2003. More is not necessarily better: prozone-like effects in passive immunization with IgG. J. Immunol. 170:3621-3630.
46. Nimmerjahn, F., and J.V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 310:1510-1512.
47. Sato, S., N. Ono, D.A. Steeber, D.S. Pisetsky, and T.F. Tedder. 1996. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:4371-4378.
48. Zhou, L.-J., H.M. Smith, T.J. Waldschmidt, R. Schwarting, J. Daley, and T.F. Tedder. 1994. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol. Cell. Biol. 14:3884-3894.